This week, we highlight Moderna’s contract extension with Rovi, a recent report that indicates the global contract development and manufacturing organization (CDMO) market is expected to grow by over $8.65 billion by 2026, Robert Califf’s return as Food and Drug Administration commissioner, an artificial ... READ MORE >
life sciences
5 things to know in life sciences: Week of Feb. 7, 2022
This week we highlight regulatory challenges for the United States and China; a softening of guidelines in the prescription of opioids; and record-breaking sales figures for Pfizer as it sees a more than 600% increase in vaccine revenue. Finally, we look at a new cartilage implant inspired by spiders and ... READ MORE >
Biopharma business outlook: Spring 2022
Drug approvals in 2021 continued at a pace consistent with prior years, but a large backlog of inspections is slowing some approvals. Cell and gene therapies investment is growing rapidly and promises substantial revenue growth in the coming years. Read about other sectors 2021 FDA approvals ... READ MORE >
The need for regulatory framework modernization: Spring 2022 medtech outlook
Having a well-defined pathway to quickly review and provide clearance for low-risk devices will help alleviate the backlog and shift resources to more critical and high-risk device applications. As the pace of innovation increases and the number of novel devices brought to market continues to grow, ... READ MORE >
Macroeconomic drivers for life sciences: Spring 2022 outlook
The three areas that middle market life sciences companies should pay specific attention to are supply chains, labor and capital markets. We anticipate a decreased appetite from private investors to pay high company valuations, but an uptick in the number of life sciences startups. This presents an ... READ MORE >
Life sciences industry outlook: Spring 2022
As the life sciences industry continues to experience growth and new scientific and operational opportunities, it also faces several challenges. Looking ahead, life sciences companies will encounter increased competition as the economy recovers. This includes competition for experienced and highly skilled ... READ MORE >
5 things to know in life sciences: Week of Jan. 31, 2022
This week, we highlight a breakthrough tubeless insulin pump which received Food and Drug Administration clearance. We also look at a telehealth pharmacy booming during the pandemic, potential breakthroughs in neurovascular research, the disparity of Asian scientists’ contributions and recognition in ... READ MORE >
5 things to know in life sciences: Week of Jan. 24
This week we look at the ethical challenges facing neuroscientists as they recruit patients for clinical research. We also look at a ride share company entering the health care space and what it may mean for clinical trial recruitment, CBD as a prevention measure for COVID-19, deltacron and ... READ MORE >
5 things to know in life sciences: Week of Jan. 17, 2022
This week, we look at antimicrobial-resistant diseases, their toll on health systems globally and the need for new treatments. We also feature the continued delays in Food and Drug Administration inspections, the demand for decentralized trials, as well as medtech's initial public offerings and their ... READ MORE >
5 things to know in life sciences: Week of Jan. 10
This week we highlight a flood of studies and approvals with a focus on leveraging new technologies, data and gene sequencing to increase patient care. While the life sciences industry has always been on the forefront of innovation, we are now seeing the various components of the ecosystem come together ... READ MORE >